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discontinuations before 6 months (RR 0.64; 95% CI 0.45 - 0.91) 
and overall adverse reactions (RR 0.51; 95% CI 0.36 - 0.73).7
Comments
No randomised studies provide information on the optimal 
time for initiating prophylaxis in adults, or on when to 
stop prophylaxis. None of the trials included in the review 
focused on patients receiving treatment with antiretrovirals. 
Current studies neither report on the effects of prolonged                     
co-trimoxazole use on bacterial resistance nor evaluate whether 
co-trimoxazole affects resistance of malaria parasites to 
sulfadoxine pyrimethamine (with which co-trimoxazole shares 
a component).
Conclusions
Co-trimoxazole is highly effective in reducing mortality and 
morbidity in HIV-infected adults and children not receiving 
antiretroviral treatment. Similar benefits are seen in early 
and advanced HIV disease. Co-trimoxazole is well tolerated, 
with minimal side-effects. Further research is required on the 
optimal time for commencement of co-trimoxazole prophylaxis 
and to evaluate its use in patients on antiretrovirals.
We thank F Desai, E Goemaere, Gail Kennedy and George 
Rutherford for their valuable feedback.
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ISSUES IN PUBLIC HEALTH
HPV vaccines: Bring me your daughters!
Carol Thomas
Our approach to cervical cancer prevention is set to change 
dramatically over the next decade with the advent of human 
papillomavirus (HPV) DNA typing, the probable demise of the 
PAP smear as we know it, and the registration of two highly 
effective vaccines against the two main HPV types (16 and 18). 
The latter account for about 70% of all cervical cancer cases 
globally and for 63% of those in South African women.1 HPV-45 
and HPV-31 account for another 10% of cases.2,3 
Except for a minority of non-mainstream, but remarkably 
visible and vocal, groups and individuals the general consensus 
worldwide is that HPV vaccines herald a new era and a 
phenomenal advance in the fight against cervical cancer, the 
most common cancer to affect women in South Africa and sub-
Saharan Africa, where the established co-factors of smoking, 
long-term oral contraceptive use, HIV co-infection and high 
parity are also operative.4 Lesotho has the unfortunate claim 
of the highest rate of cervical cancer in the world, with an age-
standardised incidence rate of 61.6 (versus our 37.5) per 100 000 
women.5 
Women and health care providers have had to make two 
paradigm shifts around cervical cancer: firstly, although 
most HPV infections clear naturally, persistent infection with 
particular genotypes of a virus are responsible for most cases of 
cervical cancer (including the less common adenocarcinoma),6   
and secondly, close contact (as in both penetrative and non-
penetrative sex) is the main mode of infection. 
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With an infective cause identified for cervical cancer and 
Jenner having led the way so many years ago, the logical next 
step was to develop a vaccine. In this case, antibody responses 
were elicited against virus-like particles (VLPs) resembling 
HPV capsid proteins. These HPV L1 VLP vaccines display 
significant immune memory.7,8
High-profile anti-breast cancer activism has ensured that 
women generally perceive breast cancer to be their main cancer 
threat. Within the private sector women primarily associate 
women’s health visits with Pap smears, resulting in effective 
opportunistic screening and low rates of cervical cancer. Such 
screening, however, may lead to high rates of investigation and 
intervention in cases where HPV infection may not persist. 
The dictum that prevention is better than cure is particularly 
relevant for cervical cancer. In the developed world cervical 
screening, independent of improving socio-economic factors, 
effectively decreases cervical cancer-associated morbidity and 
mortality,9 but in developing countries where mass screening 
does not exist and any screening remains opportunistic, 
primary prevention could be the ‘cure’. 
The inability of lay persons and health service providers to 
understand the difference between mass and opportunistic 
screening and their goals has led to confusion and apparent 
lack of commitment by public sector health care providers. 
Pap smears are synonymous with an uncomfortable, invasive 
examination, hardly something women clamour for or deem 
worthy of chaining themselves to parliament gates for. 
Whether to spare women this examination or to deal more 
rapidly with large patient loads, health service providers may 
avoid performing these examinations. Although the syndromic 
approach to sexually transmitted infections has laudable 
intent, I believe it may contribute to the dissociation of the 
crucial speculum examination from the general gynaecological 
examination. 
It is an accepted fact that the Pap smear as we know it would 
not make the grade if it were presented as a screening tool 
today. The search for appropriate screening strategies such as 
visual inspection of the cervix with acetic acid (VIA) with or 
without on-site treatment in under-resourced regions of the 
world continues, and these differ from country to country.10 
Immunisation is therefore the logical strategy, especially for our 
country and continent. There are, however, numerous barriers 
to this approach.
While the pharmaceutical industry has a right to recoup 
research and development costs and make an appropriate 
profit, we should remember that 20 years passed before 
hepatitis B vaccine was affordable to countries with the greatest 
need. Although hepatitis B vaccine offers protection against 
hepatitis B-related conditions, which include a cancer, HPV 
vaccines are the first to be developed with the sole purpose of 
preventing a cancer.
Pharmaceutical companies maintain that there will be tiered 
pricing to governments and that the cost of vaccines for large-
scale immunisation programmes will be negotiable. Whether 
the lowest negotiable price will be affordable to South Africa 
remains to be seen. However, before negotiating with the 
industry, government needs the political will to impact on the 
disease burden of our most vulnerable women. 
South Africa is one of the first African countries to register 
the vaccines, which are now available in the private sector. If 
medical aids do not pay for HPV immunisation, the cost will 
be entirely borne by individuals, mainly parents of adolescents. 
Injections are given at 0, 1 and 6 months, and the VAT exclusive 
exit price of the GlaxoSmithKline vaccine is R700 per dose. 
Add to this the cost of parental education, explanation and 
reassurance to patients, obtaining a prescription (schedule 
4), consent from parents (as in Australia), access to follow-
up, consumables and the very necessary cold chain (2 - 8ºC), 
which may be vulnerable to load shedding or inappropriate 
non-chilled transport by the patient herself, and it is evident 
that few providers are equipped to implement immunisation 
immediately. The optimal target group for immunisation 
falls just outside the usual paediatrician, general practitioner, 
immunisation nurse practitioner and gynaecologist’s 
general domain. HPV immunisation would be imminently 
implementable by adolescent medicine units if they existed,11 
or by those with a special interest in adolescent and paediatric 
gynaecology.
The Global Alliance for Vaccines and Immunisation (GAVI) 
is a global health partnership of various funders to assist with 
immunisation coverage to resource-poor countries. To be 
GAVI-eligible a country has to have a gross national income 
of less than $1 000 per capita. This effectively excludes South 
Africa.
HPV immunisation as a national strategy to decrease the 
impact of cervical cancer will also have to compete with 
rotavirus and pneumococcal vaccines, the impact of which 
can be seen much more readily than preventing a cancer 
two decades later. It is encouraging that post-quadrivalent 
immunisation surveillance in the USA indicates that the 
abnormal Pap smear incidence dropped by 43% compared with 
non-immunised women in just 3 years, which translated into a 
42% reduction in invasive procedures.12
From a national immunisation implementation point of 
view, although most of our girls attend primary school with 
attendance only dropping at secondary school level, and 
although immunisation coverage in South Africa is above 
90%, there is no formal infrastructure to reach ‘tweenies’ and 
adolescents.
Now that cervical cancer is perceived as virally induced, 
there is also the danger of STI stigmatisation.  Granny’s 
cervical cancer as a reason for increased surveillance in her 
granddaughter tends to change to ‘womb cancer’ once the non-
hereditary nature of cervical cancer is explained. 
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The introduction of the two vaccines has also spawned new 
terms like HPV-naïve and HPV-exposed. Neither is likely 
to inspire parents, who are expected to bring their young 
daughters for costly injections that will remove their ‘naïvety’. 
The concerns of parents and the general public must not be 
underestimated or ignored. Because the vaccine is given to girls 
only, there may be perceptions around prevention of pregnancy 
and population control, permission or encouragement to 
become sexually active, and gender inequity. Both vaccines 
are registered for use in females only: the bivalent GSK 
vaccine is registered for females from age 10 onward, and the 
quadrivalent MSD vaccine is registered for females aged 10 - 
26. Were there no cost constraints, and if we had adequate data 
on boys, one could argue that immunising all children would 
be desirable.
Although efficacy trials were aimed at young girls, 
immunobridging studies indicate that older women up to 
the age of 55 can be immunised against re-infection and new 
infections.13
Patients will have heard about the vaccines in the print and 
electronic media. To remain ahead, non-immunologists and 
non-vaccinologists are reaching for the books to jog dormant 
brain cells – how does the body respond to presented antigens? 
The virus manages to duck and dive the immune system 
because there is no viraemia and because the virus does not 
kill the keratinocytes of the cervical epithelium. Without cell 
death there is no inflammatory response, no pro-inflammatory 
cytokines, a meagre activation of epithelial antigen-presenting 
cells, and hence failure of natural infection to confer long-term 
protection or immunological memory. 
To date (>5 years) the vaccine appears to produce lasting 
high antibody titres with no need for booster doses. Although 
the GSK vaccine has higher persistent antibody levels (ascribed 
to its ASO4 adjuvant system) than the MSD vaccine, the 
clinical relevance of this is unclear. The GSK vaccine shows 
good cross-protection against HPV-45 (78%) and HPV-31 
(60%). Besides the vaccines against HPV-16 and 18, the MSD 
vaccine also contains vaccines against HPV-6 and 11, which 
cause 90% of genital warts.14,15 The latter do not cause cancer, 
but may be picked up on cervical screening and result in 
increased investigation and treatment. Should government 
decide on an immunisation programme, the genital wart 
burden of morbidity, distress to women and cost of treatment 
to government will have to be factored in when choosing the 
most appropriate vaccine for a national strategy. Whether 
catch-up immunisation is going to be introduced also needs to 
be addressed. Ultimately, however, cost will probably be the 
deciding factor. 
Because not all cervical cancer is prevented by the vaccines 
and because post-marketing surveillance is crucial, screening 
after immunisation cannot be eliminated. Whether this is by 
HPV typing or traditional methods is academic in the absence 
of national policy.
Due consideration must be given to oncogenic HPV-infected 
HIV-positive women in whom progress to cervical cancer is 
accelerated. We eagerly await the outcome of studies on HPV 
immunisation in HIV-positive women by Denny and others, 
and we should support national co-ordination and research 
initiatives like the Cancer Research Initiative of South Africa 
(CARISA).
Historically we have missed crucial opportunities to 
intervene in the HIV epidemic that is devastating our country. 
It would be unfortunate if we do not act to protect women, 
and thereby their families, from the impact of the HPV disease 
burden. We cannot be present when our adolescents have to 
negotiate safe sex, and can only hope that we have led by 
example and that they have developed adequate life skills to 
respond responsibly. We can, however, contribute to their long-
term well-being by ensuring that we lobby for interventions 
like HPV immunisation and in doing so protect all women, 
especially the disenfranchised and those at most risk.
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